



Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 1/17

Application Number  
09/545,316

**FIG. 1****FIG. 2**

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 2/17

Application Number  
09/545,316




FIG. 3




FIG. 4

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 3/17

Application Number  
09/545,316




FIG. 4A

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 4/17

Application Number  
09/545,316




FIG. 4B

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 5/17

Application Number  
09/545,316

Journalist Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail

Address Links

---

**Martin Block** Paper Sent: 11-Dec-1998 Review Due: 25-Dec-1998 Review Received: 22-Dec-1998

RECOMMENDATION

THIS REVIEW IS MARKED AS A DRAFT.  
IT HAS NOT YET BEEN MADE AVAILABLE TO THE EDITORS AND AUTHORS.

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Significance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Originality	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Clarity	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**COMMENTS TO THE AUTHORS**

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

<U>Specific Comments</U>

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater

THIS REVIEW IS CURRENTLY MARKED AS A DRAFT



Done

FIG. 4C

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 6/17

Application Number  
**09/545,316**

**FIG. 5****FIG. 6**

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 7/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail

Address Links

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Significance	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Originality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Clarity	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**COMMENTS TO THE AUTHORS**

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

Specific Comments

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater than 95% inhibited as indicated in the text (p. 8, par. 1).

2. Figure 1: Why are the data for only one experiment shown? It would seem to make more sense to show the data for all experiments with mean and standard errors for each point for the pooled data.

We are sorry that the reviewer seemed confused by this figure. In fact, it was a plot of mean values. We have added error bars and refined the caption to make this more clear.

3. P. 5, par. 3: The use of mean inactivation dose is perhaps the best way to analyze data fitted with the linear-quadratic model, but it is really an arcane method that will not be understood by 95% of the readers. If the authors have to use this method, they should indicate that the method heavily weights the initial part of the survival curve (for example, all data above 10% surviving fraction) and therefore, heavily weights the alpha component

Done Internet

FIG. 5A

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 8/17

Application Number  
09/545,316




FIG. 7




FIG. 8



Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 9/17

Application Number  
09/545,316




FIG. 9

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 10/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Reload Home Search Favorites History Mail Print Edit

Address: http://www.journalsoft.com/

**Journalsoft**  
To register for JournalSoft, please fill out the form.

**Fill out the form below completely to register.**

**1. Your Login Information**

Username  
Please enter the username you would like to use to login to JournalSoft.

Password  
Please enter a password that you can easily remember. Passwords are case-sensitive and should contain between 3 and 10 characters. The most secure passwords contain letters and numbers.  
Please enter your favorite password:   
Confirm password:   
Please enter your main EMAIL address:

You may enter a clue to your password to help you remember it in the future:

Done Internet

FIG. 10

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 11/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address: Links

**Journalsoft**  
To register for Journalsoft, please fill out the form.

**Fill out the form below completely to register.**

**2. Enter your contact information below**

Name:	<input type="text"/>		
Address:	<input type="text"/>		
City, State and Zip Code:	<input type="text"/>	<input type="text"/>	<input type="text"/>
Country:	<input type="text" value="- Select Continent -"/>		
Phone:	<input type="text"/>	(Not Required)	
Fax:	<input type="text"/>	(Not Required)	
Text Pager Email or Web Paging Address:	<input type="text"/>	(Not Required)	
If you have a Web Site, you can include your URL in the AD	Enter exactly as shown here: <a href="http://www.yourdomain.com">www.yourdomain.com</a> DO NOT BEGIN YOUR ADDRESS WITH "http://"		

Done Help

FIG. 11

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 12/17

Application Number  
09/545,316

The screenshot shows a web browser window titled "Journalsoft Manuscript Management System - Microsoft Internet Explorer". The browser's address bar is empty, and the toolbar includes buttons for Back, Forward, Stop, Reload, Home, Search, Favorites, History, Mail, Print, and Exit. The main content area displays a registration form for Journalsoft. On the left side of the form, there is a logo for "Journalsoft" and the text: "To register for Journalsoft, please fill out the form:". The main body of the form contains the following text:

Fill out the form below completely to register.

**3. Please tell us about your research interests**

In the space below please write a **SHORT NARRATIVE** about your research interests **OR** enter a list of **KEYWORDS** describing areas of research in which you are interested.

This information will be used to help us assign appropriate reviewers for your submissions and to find papers that you may be interested in reviewing for *Neoplasia* should you agree to serve as a reviewer.

Below this text is a large, empty rectangular text area for the user to input their narrative or keywords. At the bottom of the form, there is a "Continue" button. The browser's status bar at the bottom shows "Done" and "Home" buttons.

FIG. 12

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 13/17

Application Number  
09/545,316

The screenshot shows a web browser window titled "JournalSoft Manuscript Management System - Microsoft Internet Explorer". The address bar is empty. The browser's menu bar includes File, Edit, View, Favorites, Tools, and Help. The toolbar contains icons for Back, Forward, Stop, Refresh, Home, Search, Favorites, History, Mail, Print, and Edit. The main content area has a left sidebar with the JournalSoft logo and the text: "To register for JournalSoft, please fill out the form." The main content area contains the heading "Fill out the form below completely to register." followed by a section titled "4. Collaborator Communities". The text in this section reads: "Collaborator Communities" are groups of your peers with whom you collaborate. JournalSoft provides tools for members of collaborator communities to proof and revise manuscripts on-line prior to submission. They also allow each co-author of a paper to view the manuscript's status in the peer-review process, to view and respond to reviews and editorial decisions, and to contribute to manuscript revisions. Below this, it says: "To add people to your collaborator community, please enter their email addresses below. The members of your collaborator community will have access ONLY to those papers on which they are co-authors, or to those for which you explicitly give them permission to view." There is a large empty text box for input. At the bottom of the form area is a "Continue" button. The status bar at the bottom of the browser shows "Done" and "Internet".

JournalSoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address:

**JournalSoft**

To register for JournalSoft, please fill out the form.

**Fill out the form below completely to register.**

**4. Collaborator Communities**

"Collaborator Communities" are groups of your peers with whom you collaborate. JournalSoft provides tools for members of collaborator communities to proof and revise manuscripts on-line prior to submission. They also allow each co-author of a paper to view the manuscript's status in the peer-review process, to view and respond to reviews and editorial decisions, and to contribute to manuscript revisions.

To add people to your collaborator community, please enter their email addresses below. The members of your collaborator community will have access ONLY to those papers on which they are co-authors, or to those for which you explicitly give them permission to view.

**Continue**

Done Internet

FIG. 13

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 14/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Stop Refresh Home Search Favorites History Mail Print Edit

Address: \_\_\_\_\_

**Journalsoft**  
To register for JournalSoft, please fill out the form.

**Fill out the form below completely to register.**

**5. JournalSoft Preferences.**

Please enter your preferences so we can customize your JournalSoft experience.

Please remember that you can change these options at any time in the future.

Would you like to review papers for Neoplasia?	<input type="radio"/> YES <input type="radio"/> NO
If so, please enter any dates when you will not be available to review manuscripts (MMDDYY-MMDDYY). Enter each separate period on a new line.	<input type="text"/>
How would you like us to request reviews from you?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.
How would you like us to notify you when a manuscript which you have submitted passes through a peer-review milestone such as a review being received or an editorial decision being made?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.

21 Page

FIG. 14



Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 15/17

Application Number  
09/545,316




FIG. 15

Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 16/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Discuss Real.com

Address Links

**My JournalSoft**

View Manuscripts

Personal Data

Preferences

MetaData

Help

Logout

**Journalsoft**

You are logged in with  
**EDITOR privileges**

**CONTRIBUTING AUTHORSHIP**

You are the Corresponding Author for the following 2 manuscripts  
To view or respond to reviews please click on the thumb icons

	<p>  = Suggest acceptance   = Suggest major or minor revisions   = Suggest rejection </p>
<p>99-295</p> <p>Stegman, Lauren Daniel et al. Tasting Testing 455</p>	<p>Review 1 received 59 day(s) late on 25-Jan-2000</p> <p>Review 2 received 49 day(s) late on 11-Feb-2000</p> <p>Review 3 received 296 day(s) late on 03-Jul-1999</p>
<p>99-103</p> <p>Stegman, Lauren Daniel et al. Collateral Expression of Pro-angiogenic and Tumorigenic Properties in Intestinal Epithelial Cell Variants Selected for Resistance to Anoikis Research Article</p>	<p>Review 1 received 455 day(s) late on 21-Dec-1998</p> <p>Review 2 received 454 day(s) late on 30-Dec-1998</p>

Th Hierarchical Menu Trees Created

FIG. 16



Neoplasia Press, Inc.  
Inventors: Ross, et al.

Page 17/17

Application Number  
09/545,316

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Home Search Favorites History Mail Print Full Diskless Read from

Address: Back to Journalsoft Manuscript Management System

Links

**My JournalSoft**

View Manuscripts

Personal Data

Preferences

MetaData

Help

Logout

**Journalsoft**

You are logged in with  
**EDITOR** privileges

**Internet**

**CORRESPONDING AUTHOR**

You are listed as an author of the following 2 manuscripts.  
To view or respond to reviews please click on the thumbnails

<p>188888 Humar, Ashay, et al Benfornisation Treating Page</p>	<p>Review 1 is 17 day(s) overdue The reviewer has been reminded to submit it promptly Review 2 We are scheduling for a second reviewer</p>
<p>58-182 Lewentz, Theodor S et al HNF1B-37 Expression Causes Fluorescein Uridine-Mediated Radicalization in SW620 Human Colon Carcinoma Cells Research Article</p>	<p>Review 1 received 459 day(s) late on 22-Dec-1998 Review 2 received 453 day(s) late on 21-Dec-1998 Accepted pending major revision 01-Dec-1998 Reviews Due by 21-Jan-1999</p>

**CONTRIBUTING AUTHOR**

= Suggest acceptance  
 = Suggest major or minor revisions  
 = Suggest rejection

FIG. 17